Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) is making strides in the DNA Damage Response (DDR) inhibitor market with its lead candidate ONC010, a nanoparticle-encapsulated PNKP inhibitor designed to block a key DNA repair enzyme. The company was featured in a BioMedWire editorial that examined the emergence of drug classes beyond PARP inhibitors, highlighting Onco-Innovations' exclusive global rights to a foundational PNKP inhibitor technology portfolio.
According to the editorial, Onco-Innovations is positioning itself as an early leader in a novel class of cancer therapeutics. Preclinical data showed that ONC010 more than doubled median survival in PTEN-deficient colorectal cancer animal models while maintaining a favorable toxicity profile. The company is progressing manufacturing scale-up, IND-enabling studies, and planning first-in-human clinical development, supported by its proprietary SynoGraph causal AI platform through subsidiary Inka Health.
The DDR inhibitor market has seen significant interest, with companies like AstraZeneca plc (NYSE: AZN), Aprea Therapeutics Inc. (NASDAQ: APRE), Boundless Bio Inc. (NASDAQ: BOLD), and Foghorn Therapeutics Inc. (NASDAQ: FHTX) also developing novel therapies. Onco-Innovations' focus on PNKP, a target involved in both base excision repair and single-strand break repair, could offer a broader therapeutic window compared to existing DDR inhibitors.
“This is a pivotal time for DDR-targeted therapies,” the editorial noted, emphasizing that ONC010’s unique mechanism may address resistance to PARP inhibitors. The company’s exclusive worldwide license to patented technology for solid tumors, combined with its AI-driven platform, aims to accelerate development and identify optimal patient populations.
For more information, the full press release is available at https://ibn.fm/HH1VP. The latest news and updates on Onco-Innovations can be found at https://ibn.fm/ONNVF.
